Literature DB >> 22002086

Spectral and kinetic evidence for reaction of superoxide with compound I of myeloperoxidase.

Anthony J Kettle1, Andrej Maroz, Grant Woodroffe, Christine C Winterbourn, Robert F Anderson.   

Abstract

Superoxide and myeloperoxidase (MPO) are essential for the oxidative killing of bacteria by neutrophils. Previously, we developed a kinetic model to demonstrate that within the confines of neutrophil phagosomes, superoxide should react exclusively with MPO and be converted to hypochlorous acid. The model consists of all known reactions and rate constants for reactions of superoxide, hydrogen peroxide, and chloride ions with MPO, except for the reaction of superoxide with compound I, which could only be estimated. Compound I is a transitory redox intermediate of MPO that is responsible for oxidizing chloride ions to hypochlorous acid. To tackle the challenge of observing the reaction between two transient species, we combined stopped-flow spectrophotometry with pulse radiolysis. Using this technique, we directly observed the reduction of compound I by superoxide. The rate constant for the reaction was determined to be 5.6±0.3×10(6)M(-1)s(-1). This value establishes superoxide as one of the best substrates for compound I. Based on this value, the rate constant for reduction of compound II by superoxide was determined to be 1.2±0.1×10(6)M(-1)s(-1). Within phagosomes, the reduction of compound I by superoxide will compete with the oxidation of chloride ions so that the relative concentrations of these two substrates will affect the yield of hypochlorous acid. Characterization of this reaction confirms that superoxide is a physiological substrate for MPO and that their interactions are central to an important host defense mechanism.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002086     DOI: 10.1016/j.freeradbiomed.2011.09.019

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  7 in total

1.  Heterogeneity of hypochlorous acid production in individual neutrophil phagosomes revealed by a rhodamine-based probe.

Authors:  Amelia M Albrett; Louisa V Ashby; Nina Dickerhof; Anthony J Kettle; Christine C Winterbourn
Journal:  J Biol Chem       Date:  2018-08-22       Impact factor: 5.157

2.  Myeloperoxidase acts as a source of free iron during steady-state catalysis by a feedback inhibitory pathway.

Authors:  Dhiman Maitra; Faten Shaeib; Ibrahim Abdulhamid; Rasha M Abdulridha; Ghassan M Saed; Michael P Diamond; Subramaniam Pennathur; Husam M Abu-Soud
Journal:  Free Radic Biol Med       Date:  2013-04-25       Impact factor: 7.376

Review 3.  Multifaceted effects of Francisella tularensis on human neutrophil function and lifespan.

Authors:  Lauren C Kinkead; Lee-Ann H Allen
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

Review 4.  Myeloperoxidase: a front-line defender against phagocytosed microorganisms.

Authors:  Seymour J Klebanoff; Anthony J Kettle; Henry Rosen; Christine C Winterbourn; William M Nauseef
Journal:  J Leukoc Biol       Date:  2012-10-11       Impact factor: 4.962

5.  Conjugation of urate-derived electrophiles to proteins during normal metabolism and inflammation.

Authors:  Rufus Turner; Stephen O Brennan; Louisa V Ashby; Nina Dickerhof; Melanie R Hamzah; John F Pearson; Lisa K Stamp; Anthony J Kettle
Journal:  J Biol Chem       Date:  2018-11-01       Impact factor: 5.157

6.  Oxidative cross-linking of calprotectin occurs in vivo, altering its structure and susceptibility to proteolysis.

Authors:  Teagan S Hoskin; Jennifer M Crowther; Jeanette Cheung; Michael J Epton; Peter D Sly; Peter A Elder; Renwick C J Dobson; Anthony J Kettle; Nina Dickerhof
Journal:  Redox Biol       Date:  2019-04-13       Impact factor: 11.799

Review 7.  Biochemical and pathological studies on peroxidases -an updated review.

Authors:  Amjad A Khan; Arshad H Rahmani; Yousef H Aldebasi; Salah M Aly
Journal:  Glob J Health Sci       Date:  2014-05-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.